Skip Navigation

Annals of Oncology 2006 17(4):537; doi:10.1093/annonc/mdl067
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Vaginal oestradiol in postmenopausal women on adjuvant aromatase inhibitors
 
Around a fifth of patients on adjuvant aromatase inhibitors (AIs) suffer from atrophic vaginitis. Many ask if they can use topical oestrogen to alleviate the symptoms as conventional hormone-replacement therapy is not recommended. These topical oestrogen preparations are generally perceived to result in minimal systemic absorption of oestrogen. In this issue, however, Kendall et al. report . . . [Full Text of this Article]


   Irinotecan plus carboplatin in small-cell lung cancer
 

   Nutrient intakes and risk of non-Hodgkin's lymphoma
 

   Discuss expensive anti-cancer drugs with patients
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?